SG Americas Securities LLC Grows Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

SG Americas Securities LLC grew its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 39.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 29,341 shares of the company’s stock after acquiring an additional 8,240 shares during the quarter. SG Americas Securities LLC’s holdings in CRISPR Therapeutics were worth $998,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Wood Tarver Financial Group LLC bought a new position in shares of CRISPR Therapeutics during the fourth quarter valued at about $30,000. Ameriflex Group Inc. purchased a new stake in CRISPR Therapeutics in the 4th quarter valued at about $36,000. NBC Securities Inc. lifted its position in shares of CRISPR Therapeutics by 156,300.0% during the 1st quarter. NBC Securities Inc. now owns 1,564 shares of the company’s stock worth $53,000 after buying an additional 1,563 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of CRISPR Therapeutics in the 4th quarter worth approximately $71,000. Finally, First Horizon Advisors Inc. boosted its stake in shares of CRISPR Therapeutics by 33.4% in the 4th quarter. First Horizon Advisors Inc. now owns 2,039 shares of the company’s stock worth $80,000 after buying an additional 511 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. The Goldman Sachs Group dropped their price target on CRISPR Therapeutics from $53.00 to $47.00 and set a “neutral” rating on the stock in a report on Thursday, May 8th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a research report on Wednesday, February 19th. JMP Securities reissued a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, May 21st. HC Wainwright restated a “buy” rating and set a $65.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday, May 20th. Finally, Chardan Capital lowered their price objective on shares of CRISPR Therapeutics from $84.00 to $82.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $69.53.

CRISPR Therapeutics Price Performance

Shares of CRSP stock opened at $43.19 on Wednesday. The stock has a market capitalization of $3.73 billion, a price-to-earnings ratio of -9.56 and a beta of 1.75. The company’s fifty day simple moving average is $38.12 and its two-hundred day simple moving average is $40.77. CRISPR Therapeutics AG has a 1 year low of $30.04 and a 1 year high of $63.68.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 1,023.64% and a negative return on equity of 20.08%. During the same period in the prior year, the business earned ($1.43) EPS. The business’s revenue was up 71.6% on a year-over-year basis. Equities research analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insider Activity

In other news, insider Naimish Patel sold 3,932 shares of the company’s stock in a transaction on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total value of $141,316.08. Following the transaction, the insider now owns 6,068 shares of the company’s stock, valued at approximately $218,083.92. This represents a 39.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.